SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17-Targeting ADC for Colorectal Cancer

Phase 1SOT109Positive

AI Analysis

Summary

SOTIO has dosed the first patient in the Phase 1/2 CADENCIA-01 trial evaluating SOT109, a CDH17-targeting antibody-drug conjugate, for advanced colorectal cancer, with initial safety and efficacy signals expected within 12-18 months.

Clinical Trial Data

Phase

1/2

Outcome Details

First patient dosed in Phase 1/2 trial

Importance:5/10

Sentiment:

0.50

Phase 1/2First-in-humanADCCDH17-targetingColorectal cancerTrial initiation

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 9, 2026 12:00 PM

Read Original